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Introduction 
 Acute lymphoblastic leukemia (ALL) is the most common form of childhood cancer and 
accounts for roughly 30% of malignancies in the pediatric population
9
. Despite the relatively 
high occurrence of ALL in the pediatric population, outcomes are favorable with an overall 
survival rate reported as high as 90%
10, 11, 18, 22, 23
. Advances in chemotherapeutic agents in 
combination with risk stratification by disease burden, greater accessibility to supportive care, 
and ongoing clinical and laboratory investigations are largely credited for these improvements. 
Due to the various challenges and toxicities associated with medical management of ALL, there 
is currently no standard treatment protocol. Instead, several treatment protocols exist and are 
under continuous clinical investigation for evaluation of their efficacy and toxicity profiles. A 
common factor among treatment protocols is medical management that is based largely on the 
risk of disease burden as determined by various clinical and laboratory findings. Information 
including immunophenotype, cytogenic analysis, patient age, white blood cell (WBC) count at 
time of diagnosis, and response to initial therapy can be used to stratify patients by risk
9
. 
Intuitively the higher risk of disease burden requires a more aggressive treatment protocol to 
eradicate disease whereas a lower risk disease burden requires a less aggressive protocol and 
reduces the risk of treatment related toxicity. Regardless of risk stratification, however, the 
ultimate goal of medical management for ALL is to maximize survival while minimizing 
medication related toxicities impairing quality of life. It is reported that roughly 75-80% of 
children diagnosed with ALL are enrolled into an ongoing clinical trial aim at achieving these 
treatment related goals
9
. 
Although advances in medical management of ALL have improved survival rates, 
debilitating side effects of anti-leukemic treatment may result in significant consequences 
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regarding quality of life. Of these side effects, one of the most significant and debilitating is 
osteonecrosis (ON)
11, 22, 23
.  ON is also referred to as “avascular necrosis” or “aseptic necrosis” 
and can be defined as the death of bone tissue resulting from the loss or disruption of vascular 
supply. The presentation of ON is variable and can range from asymptomatic to debilitating with 
severe pain in the affected limb due to degenerative changes. This adverse effect of management 
can lead to loss or restricted motion and reduced quality of life. Management of this condition 
remains difficult with the primary goal of treatment aimed at preserving the native joint. 
Currently, treatment can include bed-rest, supportive care, non-weight bearing on the affected 
extremity, physical therapy exercises, and in some cases surgical intervention. Despite the 
various non-operative measures, failure to diagnosis ON in early stages may lead to bone 
collapse often requiring joint replacement even at young ages. Due to these reasons clinicians 
need a high-index of suspicion to monitor those with high risk for disease development. 
 In the pediatric ALL population, development of ON is not completely understood. 
Currently, corticosteroid induced ischemia is largely hypothesized to be a contributing factor to 
the development of ON
11
. Additionally, the current literature reports multiple risk factors for the 
development of ON to varying degrees. Some of these reported risk factors include female 
gender, age > 10 at time of ALL diagnosis, dexamethasone use, and increased dosages of 
corticosteroid during induction and delayed intensification phases of medical management
11, 22
. 
Despite these associated risk factors, variability in reported rates of ON exist among studies with 
overall incidence rates ranging from <1-17% in study populations
14, 22, 23
. 
Objective 
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The purpose of this project was to systematically review the current literature and to 
report a pooled analysis on the rates of ON following anti-leukemic treatment in the pediatric 
population. Analysis of the current literature was aimed at recognizing any relation between ON 
development and patient age at time of ALL diagnosis, gender of patient, aggressiveness of 
medical therapy utilized, and to identify any other factors related to the development of ON.  
Hypothesis 
 In pediatric patients receiving medical management for ALL, rates of osteonecrosis will 
vary with an increased risk associated with female gender, age > 10 years at time of ALL 
diagnosis, and increased aggressiveness of medical management as determined by protocol 
specific ALL risk stratification. 
Methods 
 A single investigator (JMA) conducted a search of the PubMed database on January 26, 
2017 using the search terms “(Leukemia or Cancer or steroids) AND (AVN or avascular necrosis 
or osteonecrosis) AND (pediatric or childhood or children)”. The search was limited to articles 
published in English. To increase thoroughness, this search was augmented with searches of the 
Scopus and Cochrane databases on March 28, 2017 using identical search terms and limits. 
Studies were included if they reported on rates of clinically symptomatic ON throughout the 
entirety of treatment in ALL patient populations < 18 years of age. Exclusion criteria included 
Level V evidence, laboratory studies, radiographic studies, systematic reviews, clinical 
development trials, and studies reporting preliminary results. 
 Studies meeting all inclusion criteria were reviewed individually and the following data 
was extracted: year of publication, study design, enrollment time period, geographical location, 
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number of enrolled patients (total, male, and female), mean age at ALL diagnosis, treatment 
protocol, total number and incidence rates of ON development (total, male, and female), number 
and incidence rates of ON in patients > 10 years at time of ALL diagnosis, number and incidence 
of ON in patients < 10 years at time of ALL diagnosis, mean age of ALL diagnosis for patients 
who developed ON, mean duration of time from ALL diagnosis and development of ON, number 
and incidence of ON development based on disease risk stratification, number and incidence of 
ON development based on immunophenotype, anatomical location of ON, and mean number of 
joints affected per patient.  
Search Results 
 The search resulted in 764 cumulative citations (Figure 1). Of these citations, 117 were 
immediately excluded as they were determined to be duplicate studies. The titles of the 
remaining 647 citations were reviewed and 375 studies were excluded based on the manuscript 
title being obviously unrelated to this review. Abstracts were then reviewed for the remaining 
272 citations which resulted in an additional 160 articles excluded. The final 112 citations were 
reviewed in their entirety which resulted in 86 additional exclusions based on the manuscript. 
The final number of studies meeting inclusion criteria for this systematic review and meta-
analysis was 26. Each manuscript was reviewed individually and data for each was extracted as 
described in the methods section. After review of the 26 articles it was determined that two of the 
included studies were published by the same author, under the same treatment protocol, in the 
same geographical region, and during overlying time periods. Therefore, it was determined that 
the two studies reported on identical patient populations and data from the most recently 
published article was used for this review as to not duplicate patient outcomes. This exclusion 
resulted in a total of 25 studies included in this review (Tables 1-4). 
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Statistics 
A meta-analysis was conducted on the pooled proportions of symptomatic ON in the 
included studies. A random effects model was used to calculate the pooled estimated proportions 
and 95% confidence intervals (CI). Heterogeneity between the studies was quantified with the I
2
 
statistic. Separate forest plots were generated to explore the rates of ON in various subgroups 
including gender, age (<10 years vs. > 10 years), and risk of disease burden of ALL. These 
included proportional estimates for each subgroup as well as the risk ratio between the 
subgroups. Meta-regression was used to explore the effect of time (based on date of manuscript 
publication) and geographical location (all other countries versus European countries) on the 
proportion of symptomatic ON. The alpha level of all statistics was set at 0.05. All statistical 
analysis was performed using Stata 14 (StataCorp. 2015. Stata Statistical Software: Release 14. 
College Station, TX: StataCorp LP). 
Statistical Results 
 The 25 included studies reported on 14,043 children treated for ALL and revealed a total 
of 509 cases of ON accounting for a pooled incidence rate of 4.4% (CI 3.5 – 5.3%, Figure 2). 
The mean age of ALL diagnosis for those who developed ON was reported in 20 studies and 
resulted in a pooled mean of 12.46 years. The mean onset of timing from ALL diagnosis to 
clinical diagnosis of ON was reported in 19 studies with a pooled mean of 16.58 months.  
Female versus Male Gender 
 The included studies reported on 5987 male and 4612 female patients with the greater 
proportion of ON presenting in females compared to males (6.6%, CI 4.4 – 9.3% compared to 
4.2%, CI 2.5 – 6.3%; Figure 3). Further statistical analysis of these studies revealed increased 
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relative risk for patients of female gender compared to male gender in the development of ON 
(RR 1.56, CI 1.28 – 1.90; Figure 4). 
Age < 10 Years versus Age > 10 Years at ALL Diagnosis 
 Twenty of the included studies reported ON rates specific to age > 10 years compared to 
age < 10 years at time of ALL diagnosis. Cumulatively, 750 patients diagnosed at age > 10 years 
were compared to 2573 patients at age < 10 years at time of ALL diagnosis. The greater 
proportion of ON occurred in patients aged > 10 years compared to aged < 10 years at time of 
ALL diagnosis (13.5%, CI 9.3 – 18.3% compared to 1.2%, CI 0.5 – 2.1%; Figure 5). Further 
statistical analysis of these studies revealed increased risk for patients aged > 10 years at time of 
ALL diagnosis as compared to those < 10 years of age at time of ALL diagnosis in the 
development of ON (RR. 9.35, CI 5.67 – 15.43; Figure 6). 
Risk of Disease Burden 
 Nineteen studies reported on the rates of ON by disease risk stratification as determined 
by treatment protocol. Statistical analysis was conducted by pooling data from “low” to 
“medium” risk (or equivalent) versus “high” to “very high” risk. Cumulatively, 155 patients 
were classified as “low” to “medium” risk while 247 were categorized as “high” or “very high” 
risk. The greater proportion of ON occurred in high risk disease burden compared to low risk 
disease burden (7.5%, CI 5.2 – 10.1% compared to 2.9%, CI 1.5 – 4.8%; Figure 7). Further 
statistical analysis of these studies revealed increased risk for patients stratified as “high” or 
“very high” risk as compared to “low” or “medium” risk in the development of ON (RR 2.16, CI 
1.47 – 3.18; Figure 8). 
Immunophenotype 
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 Only 8 of the included studies reported on the rates of ON development based on 
immunophenotype. Pooling of this data resulted in 128 patients classified as B-cell leukemia 
while 36 were categorized as T-cell leukemia with the greater proportion of ON occurring in T-
cell versus B-cell (5.88% compared to 4.76%). 
Affected Limbs 
 Eighteen studies reported on the specific limb(s) affected by ON per patient. Overall, the 
studies reported on 399 patients who developed 994 clinically symptomatic cases of ON (mean, 
2.66 affected limbs per patient). Based on the specific limb(s) involved, ON developed in the 
hip/femoral head (337), knee (309), foot/ankle (162), shoulder/scapula (79), elbow (44), femur 
(28), tibia (19), and wrist/hand (16).  
Meta-Regression Analysis 
 Meta-regression was conducted on rates of ON over time (0.0129 increase per year, p = 
0.159; Figure 9) and rates of ON based on geographic location of study (0.0027 increase in 
European countries, p = 0.876; Figure 10). 
Discussion 
 The goal of this systematic review with meta-analysis was to consolidate the available 
literature in order to report on overall incidence rates and risk factors for the development of ON 
in pediatric patients being medically managed for ALL. The search criteria and multiple 
databases were specifically chosen in an attempt to be as comprehensive as possible. Although 
previous studies have already reported associations between risk of ON development and female 
gender, age > 10 years at time of ALL diagnosis, and increased corticosteroid use there is 
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currently no wide-ranging systematic review with meta-analysis to investigate these associations 
in totality and to report on the pooled results of these studies. To the best of the authors’ 
knowledge, this investigation is the first to do so. 
 Overall, the cumulative proportion of symptomatic ON development in this patient 
population was determined to be 4.4% (CI 3.4 – 5.3%). This investigation reported on the 
cumulative incidence in an aggregated pool of 14,043 patients and, to the best of the authors’ 
knowledge, is the most inclusive report on rates of ON in the pediatric population. Of the 
included studies the number of included patients ranged from 109 in the investigation by Hogler 
et al.
8
 to 1,951 in the investigation reported by Burger et al.
4
 In addition, rates of ON from the 
included studies ranged from just 0.81% in the investigation by Madadi et al
16
 to 17.74% in the 
investigation reported by Kuhlen et al.
14
 This wide variation across studies is similarly cited in 
the literature and is precisely the reason the efforts of this meta-analysis were necessary. All four 
studies were conducted between the years 2005-2014 and reported on clinically symptomatic 
development of ON that was confirmed radiographically. Although all studies used different 
treatment protocols, all protocols utilized corticosteroids and stratified patients by risk to 
determine specific treatment pathways within the protocols. The variance among incidence rates 
may be due to random chance between studies or may be related to other risk factors that were 
not investigated in this review. 
From the pooled analysis of the 25 included studies, our results support the current 
literature as we report increased risk for female gender and those > 10 years of age at time of 
ALL diagnosis. In regards to gender, 229 females were found to have developed symptomatic 
ON attributing to an accumulative incidence rate of 6.6% (CI 4.4 – 9.3%) as compared to 191 
males attributing to an accumulative incidence rate of 4.2% (CI 2.5 – 6.3%). From this it was 
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determined that females have a 1.56 RR (CI 1.28 – 1.90) of developing symptomatic ON as 
compared to males. In regards to age, 339 patients aged > 10 at time of ALL diagnosis were 
found to have developed symptomatic ON attributing to an accumulative incidence rate of 13.5% 
(CI 9.3 – 18.3%) as compared to 79 patients aged < 10 at time of ALL diagnosis attributing to an 
accumulative incidence rate of only 1.2% (CI 0.5% - 2.1%). From this it was determined that 
those aged > 10 years at time of ALL diagnosis have a 9.35 RR (CI 5.67 – 15.43) of developing 
symptomatic ON as compared to those < 10 years at time of ALL diagnosis. The risk attributed 
to age was the greatest risk factor associated with the development of symptomatic ON revealed 
in this investigation. The association between female gender and age > 10 at time of ALL 
diagnosis with the development of ON is well reported in the literature, however complete 
understanding of the pathophysiological mechanisms behind these relationships has not been 
fully understood. Possible mechanisms behind these associations may include hormones, timing 
of skeletal development, and genetic predispositions which may become the basis for future 
investigations. 
In regards to chemotherapeutic agent and corticosteroid use, this meta-analysis utilized 
risk stratification as determined by the treatment protocol as a surrogate for level of 
aggressiveness in medicinal treatment. Essentially, the treatment protocols described in each 
manuscript were extremely detailed with various clinical and laboratory variables used to 
determine the appropriate course of treatment. In addition, determining the dosage and frequency 
of medication administration to each patient was essentially impossible unless it was specifically 
reported by the investigators. Part of the reason for this difficulty is that the stratification of 
patients is not only based on clinical and laboratory values at the time of ALL diagnosis, but can 
also be changed based on initial response to therapy. Even patients within the same stratification 
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group within an identical study protocol may have been exposed to varying dosages and 
frequencies of medications. Therefore, based on the variability between protocols and extreme 
detail within protocol without specific reporting of dosage and frequency of medication 
administration it was not plausible to compare studies and draw overall conclusions based on 
specific drug therapy. Consequently, it was decided to use level of risk stratification as a 
surrogate for aggressiveness of treatment. The  theory behind this decision was that regardless of 
protocol utilized, the aggressiveness of medical treatment as determined by dosage, frequency, 
and drug utilized is correlated with risk (i.e., the higher the risk stratification the more aggressive 
the medical treatment of the disease). Based on this, patients were classified into “high” or “very 
high” risk versus “low” or “medium” risk for comparison. From the pooled analysis those with 
higher risk of disease burden were found to have an overall incidence of 7.5% (CI 5.2 – 10.1%) 
as compared to those determined to be “low” or “medium” risk who suffered an incidence rate of 
2.9% (CI 1.5 – 4.8%). From this it was determined that those with higher risk of disease burden 
had a 2.16 RR (CI 1.47 – 3.18) of developing symptomatic ON as compared to those with low 
risk of disease burden. From these results, this study supports the theory that more aggressive 
medical management is associated with higher proportions of symptomatic ON development.   
In an attempt to determine if the rates of symptomatic ON are related to time or 
geographic location of the patient population a meta-regression analysis was performed. When 
evaluating rates of ON over time, analysis revealed a 0.0129 increase per year (p = 0.159) based 
on the included studies. A potential reason for this increase could be an association between ON 
development and the correlated improvement in patient survival. In other words, the rates of ON 
may be slightly increasing as the rates of survival increase due to various factors such as 
extended exposure to medical therapy and more prolonged follow-up for survivors. In regards to 
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meta-regression of geographical location all other countries were compared to European 
countries with a 0.0027 increase (p = 0.876) in European studies. There does not appear to be a 
significant effect of ON rates based on this evaluation. 
Finally, this investigation found that of the 20 studies that reported on limb involvement 
there was a mean of 2.66 limbs affected per patient presenting with symptomatic ON. This is 
important for a clinician to consider as it appears that the individuals who develop symptomatic 
ON may be at risk in multiple sites. This could lead a clinician to consider radiographically 
screening other limbs of an affected patient to rule out involvement in asymptomatic sites. 
Additionally, the most commonly affect joints/limbs were the hip or proximal femur (348), knee 
(323), and foot/ankle (169) which is consistent with the current literature. The weight bearing 
joints of the body appear to be more commonly affected in patients which may be the result of 
increased strain and trauma to these joints and also may be in part due to the increased likelihood 
of complaining of pain in these joints  
Study Limitations 
 The greatest limitation to this systematic review and meta-analysis is the variability in 
treatment protocol used during treatment. The variability between study protocols, lack of 
reported detail on dosage and frequency of medicinal administration in investigations, and re-
stratification of disease and treatment based on initial response made it extremely difficult to 
extract information for caparison of drug, dosage, and frequency of administration. In addition, 
this review and meta-analysis was specific to clinically symptomatic pain which was confirmed 
radiographically to be ON. Due to the fact that ON can present with varying degree of pain, this 
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analysis may underestimate the true rate of ON in this population as all studies reporting on 
screening or preventative measures for diagnosis of asymptomatic ON were excluded. 
Conclusions and Future Work 
Based on analysis of the current literature, ON as an adverse effect of pediatric ALL 
treatment occurs in 4.4% of patients with increased risk in females, those > 10 years at diagnosis, 
and those with high risk disease burden which is correlated with more aggressive medicinal 
treatment. Further investigations into this subject should be focused on determining any 
association between cumulative dosages of medical therapies and the development of ON. In 
addition, due to the importance of early diagnosis in patients with ON further investigations into 
preventative screening modalities for cases of asymptomatic ON in susceptible populations are 
necessary. The benefits of screening for asymptomatic cases of ON need to be weighed against 
the financial implications of conducting screening tests and, more importantly, against the risks 
involved in exposing young children to radiation.  
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Figure 1: Flow dagram for enrollement of eligibile studies.  
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Figure 2: Forest plot for cumulative proportion of ON development in children treated for ALL 
in included studies. 
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Figure 3: Proportion of ON based on gender. 
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Figure 4: Relative risk of developing ON by gender. 
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Figure 5: Proportion of ON development by age at time of ALL diagnosis. 
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Figure 6: Relative risk for development of ON based on age at time of ALL diagnosis. 
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Figure 7: Proportion of ON development by risk of disease burden. 
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Figure 8: Relative risk for development of ON based on risk of disease burden. 
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Figure 9: Meta-regression, rates of ON over time. 
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Figure 10: Meta-regression, rates of ON based on geographical location of study. 
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Authors Study Design Geographic Location Treatment Regimen 
Riccio et al.
22
 (2016) Retrospective Cohort Naples, Italy Corticosteroids and Cytostatic Agents 
Karas-Kuzelicki et al.
12
 (2016) Retrospective Cohort Ljubljana, Slovenia 
Various Pediatric Oncology Group (POG) and Berlin-Frankfurt-
Munster (BFM) Protocols 
Padhye et al.
20
 (2016) Retrospective Cohort Sydney, Australia ANZCHOG ALL8 Trial 
den Hoed et al.
6
 (2015) Prospective Cohort The Netherlands Dexamethasone based Dutch Child Oncology Group- ALL9 Protocol 
Badhiwala et al.
2
 (2015) Retrospective Cohort Ontario, Canada Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 
Toft et al.
28
 (2015) Prospective Cohort 
Sweden, Norway, Denmark, Finland, Iceland, 
Estonia, Lithuania 
NOPHO ALL2008 
Chen et al.
5
 (2015) Retrospective Cohort Northern Taiwan Taiwan Pediatric Oncology Group- ALL-2002 Protocol 
Kuhlen et al.
14
 (2014) Retrospective Cohort Germany CoALL 07-03 Protocol 
Hyakuna et al.
11
 (2014) Retrospective Cohort Okinawa, Japan ALL941, ALL2000, and ALL2004 Protocols 
Subset of 3 Clinical Trials 
Retrospective Cohort Okinawa, Japan ALL941 
Retrospective Cohort Okinawa, Japan ALL2000 
Retrospective Cohort Okinawa, Japan ALL2004 
Leblicq et al.
15
 (2013) Retrospective Cohort Quebec, Canada DFCI 2000-01 and 2005-001 Protocols 
Madadi et al.
16
 (2011) Retrospective Cohort Tehran, Iran Corticosteroids and Cytostatic Agents 
te Winkel et al.
27
 (2011) Prospective Cohort The Netherlands Dexamethasone based Dutch Child Oncology Group- ALL9 Protocol 
Elmantaser et al.
7
 (2010) Retrospective Cohort Glasgow, UK UKALL97, UKALL97/01, or UKALL2003 
te Winkel et al.
26
 (2008) Retrospective Cohort The Netherlands Dutch Childhood Oncology Group (DCOG)-ALL9 Treatment Protocol 
Hogler et al.
8
 (2007) Retrospective Cohort Austria ALL BFM 90, 95, 99 (Pilot), and 2000 Protocols 
Sawicka-Zukowska et al.
24
 
(2006) 
Retrospective Cohort Poland ALL BFM 95, BFM ALL IC 2002, and New York Protocols 
Burger et al.
4
 (2005) Retrospective Cohort Germany ALL-BFM 95 Protocol 
Arico et al.
1
 (2003) Retrospective Cohort Palemo, Italy AIEOP-ALL 95 Protocol 
Strauss et al.
25
 (2001) Retrospective Cohort Boston, Mass. (USA) DFCI ALL 87-01 and 91-01 Protocols 
Mattano Jr. et al.
17
 (2000) Retrospective Cohort 
Kalamazoo, MI; Los Angeles, CA; and Chicago, 
IL (USA) 
Children's Cancer Group (CCG-1882) Protocol 
Wei et al.
29
 (2000) Retrospective Cohort Philadelphia, PA (USA) CCG-1882 Protocol 
Report from the PHWGCRC*
21
  
(1999) 
Retrospective Cohort Czech Republic 
ALL-BFM 83, 90, 95. ALL-Slovak Protocols 0276, 0380, 0486, 0491, and 
0591 
Korholz et al.
13
 (1998) Retrospective Cohort Germany CoALL 3-85, 4-89, 5-92. BFM-ALL 86 and 90. 
Murphy and Greenberg
19
 
(1990) 
Retrospective Cohort Ontario, Canada Modified BFM Protocol 
Bomelburg et al.
3
 (1990) Retrospective Cohort Germany DAL and BFM Protocols 
TOTAL (n=25) 
  
  
Table 1: Included studies, study design, geographic location of study, and treatment protocol utilized. 
*Pediatric Hematology Working Group of the Czech Republic and Collaborators 
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Authors 
No. Enrolled 
Patients (M/F) 
Mean Age at ALL 
Diagnosis 
No. ON Events 
(M/F) 
Incidence % (M/F) 
Mean Age Patients Diagnosed (ALL) 
Developed ON 
Onset Timing of ON (From ALL 
Diagnosis) 
Riccio et al.22 (2016) 328 (204/124) 6.17 years 4 (1/3) 1.2% (0.005%, 2.42%) 12 years (mean) 12.5 months (mean) 
Karas-Kuzelicki et al.
12
 (2016) 313 (165/148) 5.9 years 12 (7/5) 3.83% (4.24%, 3.38%) 11.3 +/- 5.9 years (mean)   
Padhye et al.
20
 (2016) 251 (143/108)   18 (7/11) 7% (5.2%, 11.2%) 13.05 years (median, 4.3-16.7) 1.15 years (median, 0.25-2.12) 
den Hoed et al.
6
 (2015) 466 (291/175) 6.02 years 30 (14/16) 6.4% (0.05%, 10.06%) 13.5 years (median, 5-17.1) 14 months (median, 1-33) 
Badhiwala et al.
2
 (2015) 208 (115/93) 5.4 years 21 (8/13) 10.1% (6.96%, 13.98%) 9.3 years (mean) 69.2 weeks (mean) 
Toft et al.
28
 (2015) 934 (502/432) 5.3 years 37 (not reported) 3.96% (not reported)     
Chen et al.
5
 (2015) 245 (150/95)   6 (1/5) 2.45% (0.67%, 5.26%) 13.3 years (median age, 11.6-16.4) 2.5 years (median, 1.1-7.5) 
Kuhlen et al.
14
 (2014) 124 (72/52)   22 (9/13) 17.74% (12.5%, 25.0%) 11 years (median age) 13.9 months (median, 3.6-52.2) 
Hyakuna et al.
11
 (2014) 1095 (610/485)   16 (4/12) 1.46% (0.66%, 2.47%) 11.5 years (median, 5-16y)   
Subset of 3 Clinical Trials 
464 (not reported)   4 (not reported) 0.86%   
56.5 weeks (median, 32-264) 
305 (not reported)   2 (not reported) 0.66%   
326 (not reported)   10 (not reported) 3.07%   66 weeks (median, 37-120) 
Leblicq et al.15 (2013) 220 (124/96) 
4.8 years (median, 
1.2-18) 
17 (11/6) 7.73% (8.87%, 6.25%) 11 years (median, 2.7-16.6) 13.4 months (median, 2.5-34) 
Madadi et al.16 (2011) 865 (not reported)   7 (4/3) 0.81% 10.2 years (mean, 5-13) 20 months (median, 10-91) 
te Winkel et al.27 (2011) 679 (416/263) 6.36 years 38 (18/20) 5.6% (4.33%, 7.60%) 12.5 years (mean), 13.5 years (median) 1.2 years (mean, 0.1 to 2.7) 
Elmantaser et al.7 (2010) 186 (110/76) 
5.3 years (median, 
1.7-13.6) 
18 (not reported) 9.70% 12.2 years (median, 6.8-14.9) 29 months (median, 8.8-48) 
te Winkel et al.26 (2008) 161 (93/68)   24 (12/12) 14.91% (12.90%, 17.65%) 13.8 years (median, 4.0-17.2)   
Hogler et al.8 (2007) 109 (61/48) 
5.16 years (median, 
0.07-17.33) 
10 (6/4) 9.17% (9.84%, 8.33%) 
12.78 years (median, 6.93-16.30) [this is age at 
event] 
15.85 months (median, 1.15-52.01) 
Sawicka-Zukowska et al.24 (2006) 150 (not reported)   6 (5/1) 4% (not reported) 16.23 years (mean) 1.47 years (mean) 
Burger et al.4 (2005) 1951 (1106/845)   31 (14/17) 1.59% (1.27%, 2.01%)     
Arico et al.1 (2003) 1421 (752/669)   15 (3/12) 1.06% (0.4%, 1.79%)   17 months (median, 8-45) 
Strauss et al.25 (2001) 176 (95/81)   13 (not reported) 7.39% (not reported)   14 months (median, 10-24) 
Mattano Jr. et al.17 (2000) 1409 (790/619) 10.1 years (mean) 111 (51/60) 7.88% (6.46%, 9.69%) 13.6 years (mean, 3.8-18.5)   
Wei et al.29 (2000) 202 (119/83) 
6.5 years (mean, 1-
18) 
8 (5/3) 3.96% (4.20%, 3.61%) 9.92 years (mean, 3.58-15.67) 30 months (mean, 8-74) 
Report from the PHWGCRC*
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(1999) 
665 (not reported)   9 (2/7) 1.35% (not reported) 13.75 (median, 9.25-17.0), 13.65 (mean) 
13 months (median, 5-25), 13 months 
(mean) 
Korholz et al.13 (1998) 121 (69/52) 
4 years (median, 1-
17) 
10 (6/4) 8.26% (8.70%, 7.69%) 9.55 years (mean, 3-17) [this is age at event] 21.3 months (mean, 7-40) 
Murphy and Greenberg19 (1990) 228 (not reported)   5 (3/2) 2.19% (not reported) 13.08 years (mean, 9.5-16.7) 12.4 months (mean, 10.5-18) 
Bomelburg et al.3 (1990) 441 (not reported)   5 (not reported) 1.13% (not reported) 7.8 years (mean, 1-13) 
13.6 months (mean, 12-15 for first ON 
lesion) 
TOTAL (n=25) 14043 (5987/4612) 6.90 years 509 (191/229) 4.4% (4.2%, 6.6%) 12.46 years 16.58 months 
Table 2: Included studies, enrolled patients, mean age, incidence rates of ON, mean age of ALL diagnosis for those who developed ON, and onset of ON timing. 
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Authors 
Incidence (%) 
>10y 
Incidence (%) 
<10y 
Rates of ON Based on Risk Stratification 
Rates of ON Based on 
Immunophenotype 
BCP T 
Riccio et al.22 (2016) 4 (not reported) 0 Standard- 0/180 (0%) Intermediate- 1/49 (2.04%) High- 3/99 (3.03%) 
  
Karas-Kuzelicki et al.
12
 (2016)       
  
Padhye et al.
20
 (2016) 16 (29%) 2 (1.02%) Standard- 2/59 (3.39%) Medium- 12/159 (7.55%) High- 0/5 (0%) 
Very High- 4/28 
(14.29%)   
den Hoed et al.6 (2015) 28 (22.05%) 2 (0.59%) Non-High Risk- 20/330 (6.06%) High Risk- 10/136 (7.35%) 25/379 (6.60%) 5/68 (7.35%) 
Badhiwala et al.
2
 (2015) 11 (35.5%) 10 (5.6%) Standard Risk- 10/130 (7.69%) High- 11/78 (14.1%) 
  
Toft et al.
28
 (2015) 18 (9.23%) 11 (1.49%)   
  
Chen et al.
5
 (2015) 6 (10.91%) 0 (0%) Standard- 0/90 (0%) High- 5/86 (5.81%) Very High- 1/69 (1.45%) 6/217 (2.76%) 0/28 (0%) 
Kuhlen et al.
14
 (2014) 13 (34.21%) 9 (10.47%) Low- 4/53 (7.55%) High- 18/69 (26.09%) 16/102 (15.69%) 5/20 (25.0%) 
Hyakuna et al.11 (2014) 12 (4.82%) 4 (0.47%) Standard- 1/630 (0.16%) High and High-High- 15/465 (3.23%) 9/748 (1.20%) 3/102 (2.94%) 
Subset of 3 Clinical Trials 
          
          
          
Leblicq et al.15 (2013) 
10 (not 
reported) 
7 (not reported) Standard- 6/129 (4.65%) High- 11/91 (12.09%)     
Madadi et al.16 (2011) 5 (not reported) 2 (not reported) Standard- 2 (not reported) High- 5 (not reported)     
te Winkel et al.27 (2011) 
33 (not 
reported) 
5 (not reported) Non-High Risk- 27/473 (5.71%) High-Risk- 11/206 (5.34%)     
Elmantaser et al.7 (2010)           
te Winkel et al.26 (2008)     Non-High Risk- 18/111 (16.22%) High-Risk- 6/50 (12.0%) 20/136 (14.71%) 4/25 (16.0%) 
Hogler et al.8 (2007) 6 (25.0%) 4 (4.71%) Standard- 2/36 (5.56%) Medium- 4/53 (7.55%) High- 4/18 (22.22%)     
Sawicka-Zukowska et al.
24
 
(2006) 
6 (not reported) 0       
Burger et al.4 (2005) 28 (7.14%) 3 (0.19%) Standard- 1/679 (0.15%) Medium- 25/1046 (2.39%) High- 5/226 (2.21%) 5/450 (1.11%) 5/250 (2.0%) 
Arico et al.1 (2003) 12 (4.82%) 3 (0.26%) Standard-  1/98 (1.02%) Intermediate- 9/1121 (0.8%) High- 5/202 (2.48%)     
Strauss et al.25 (2001)     Standard- not reported High- not reported     
Mattano Jr. et al.17 (2000) 107 (11.98%) 4 (0.78%) All patients evaluated in this study were considered "High" risk 47/656 (7.16%) 11/109 (10.09%) 
Wei et al.29 (2000) 5 (not reported) 3 (not reported) Low- 2/144 (1.39%) High- 6/58 (10.34%)     
Report from the 
PHWGCRC*21  (1999) 
8 (3.90%) 1 (0.19%) Standard- 2 (not reported) Medium- 5 (not reported) High- 2 (not reported)     
Korholz et al.13 (1998) 5 (25%) 5 (4.72%) Standard 1/66 (1.52%) High- 9/55 (16.36%) 0/3 (0%) 3/10 (30%) 
Murphy and Greenberg19 
(1990) 
4 (not reported) 1 (not reported) Standard- 0/115 (0%) High- 5/113 (4.4%)     
Bomelburg et al.
3
 (1990) 2 (not reported) 3 (not reported)       
TOTAL (n=25) 339 (13.5%) 79 (1.2%) Low to Medium (or Standard to Intermediate) Risk: 155 (2.9%) High or Very High Risk: 247 (7.5%) 128 (4.76%) 36 (5.88%) 
Table 3: Included studies and incidence of ON by various risk factors (age, risk stratification, and immunophenotype). 
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Authors 
Cumulative Number of Joint Affected by Location Joints Affected Per Patient 
Diagnosed with ON Hip Femur Tibia Knee Foot/Ankle Shoulder/Scapula Elbow Wrist/Hand 
Riccio et al.
22
 (2016) 7 0   0 0 1 0 0 2 
Karas-Kuzelicki et al.
12
 (2016)                   
Padhye et al.
20
 (2016) 18     27 12 7 1   3.61 
den Hoed et al.
6
 (2015) 19     22 6 4 1 1 1.76 
Badhiwala et al.
2
 (2015) 14     18 19       2.43 
Toft et al.
28
 (2015)                   
Chen et al.
5
 (2015) 11   2 1 2 1     2.83 
Kuhlen et al.
14
 (2014) 17     32 12 8 1   3.18 
Hyakuna et al.
11
 (2014) 16 2   12 1       1.94 
Subset of 3 Clinical Trials 
7               1.75 
1     2 1       2 
8 2   10         2 
Leblicq et al.
15
 (2013) 11     8 23       2.47 
Madadi et al.
16
 (2011) 11               1.57 
te Winkel et al.
27
 (2011) 45     56 19 8 1 1 3.42 
Elmantaser et al.
7
 (2010) 9     13   7     1.61 
te Winkel et al.
26
 (2008)                   
Hogler et al.
8
 (2007) 8   8   10 4     3 
Sawicka-Zukowska et al.
24
 (2006)                   
Burger et al.
4
 (2005) 11 2   14 7 4     # 
Arico et al.
1
 (2003) 19   2 1 5 2     1.93 
Strauss et al.
25
 (2001)   7 7     3 13 3 2.54 
Mattano Jr. et al.
17
 (2000) 86     99 46 29 24 11 2.66 
Wei et al.
29
 (2000) 12     8 3 2 2   3.38 
Report from the PHWGCRC*
21
  (1999) 7 7     1       1.67 
Korholz et al.
13
 (1998)                 6.6 
Murphy and Greenberg
19
 (1990) 5 6     2 2 1   3.2 
Bomelburg et al.
3
 (1990) 6 4       1     2.2 
TOTAL (n=25) 348 30 19 323 169 83 44 16 2.66 
Table 4: Included studies, enrolled patients, mean age, incidence rates of ON, mean age of ALL diagnosis for those who developed ON, and onset of ON timing. 
*Pediatric Hematology Working Group of the Czech Republic and Collaborators 
#This data was reported in number of patients affected instead of cumulative joints affected (not included in pooled analysis) 
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